Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,180.74 +52.95 (+1.03%) Dow
38,852.27 +176.59 (+0.46%) Nasdaq
16,349.25 +192.92 (+1.19%) Bitcoin USD
63,279.44 -697.69 (-1.09%) CMC Crypto 200
1,367.10 +54.47 (+4.15%)
VRTX Sep 2024 410.000 put
| Previous close | 24.10 |
| Open | 24.10 |
| Bid | 22.80 |
| Ask | 26.60 |
| Strike | 410.00 |
| Expiry date | 2024-09-20 |
| Day's range | 24.10 - 24.10 |
| Contract range | N/A |
| Volume | |
| Open interest | 18 |
GuruFocus.comVertex Pharmaceuticals Q1 2024 Earnings: Surpasses Revenue Expectations with Strategic Expansions
Comprehensive Analysis of Vertex Pharmaceuticals' Financial Performance and Strategic Initiatives
ReutersVertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments
(Reuters) -Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its blockbuster cystic fibrosis treatments. Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation. Vertex reported adjusted earnings per share of $4.76 on revenue of $2.69 billion, topping market estimates $4.06 on revenue of $2.58 billion, according to LSEG data, for the quarter ended March 31.
Business WireVertex Reports First Quarter 2024 Financial Results
BOSTON, May 06, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance.
